Postdoctoral Research Fellow

The Department of Pathology and Cell Biology at Columbia University Irving Medical Center seeks a highly qualified Postdoctoral Research Fellow to develop, validate and run High Resolution Mass Spectrometry-based quantitative drug and exposomics assays in support of the care of patients with obesity and diabetes and in support of patients with psychiatric disorders.

The ARPA-H funded project is part of a multi-institutional effort (IndiPHARM) led by Dr Gary Miller from Columbia University, Mailman School of Public Health. The project itself is led by Drs Serge Cremers, and Alex Lyashchenko who will be overseeing the activities of the fellow in the Clinical Pharmacology and Toxicology Laboratory of the Department of Pathology and Cell Biology at Columbia University Irving Medical Center.

The work is to lead to several scientific publications and will provide a unique opportunity for clinical pathologists and clinical chemists to gain experience in the development of highly complex mass spectrometry assays and their application in patient care. For other MDs, PhDs, and/or PharmDs with experience in this area, the work not only provides a unique opportunity to develop highly complex mass spectrometry assays for patient care, but also an opportunity to be trained as clinical laboratory director and clinical pharmacologist.

Job Function

Develop, validate and implement High Resolution Liquid Chromatography Mass Spectrometry (Exploris-120)– based panel assays to quantify drugs, metabolomic and exposomic markers in blood of patients in support of their care. The panel assays are to be approved for patient care by NY State Department of Health.

The panels are focused on drugs, metabolomic, and exposomic markers relevant for treatment patients with diabetes and obesity and for the treatment of patients with psychiatric diseases.

The development of the assays will take place in close collaboration with the other investigators involved in the IndiPHARM project, especially Drs Gary Miller and Randolph Singh’s group from Columbia’s Mailman School of Public Health and Dr Douglas Walker from Emory University.

The fellow will be involved in the clinical pharmacological interpretation of these highly complex assays for individual patients and is expected to publish several papers from these activities.

If eligible, the fellow is expected to apply for a Laboratory Director Certificate of Qualification in Therapeutic Substance Monitoring / Quantitative Toxicology from New York State Department of Health.